Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported Q1 2026 GAAP total revenues of $268 million, driven by DAYBUE net sales of $101 million (+20% YoY) and NUPLAZID net sales of $167 million (+5% GAAP YoY). The company reaffirmed full‑year 2026 GAAP revenue guidance of $1.22–$1.28 billion and expects Phase 2 remlifanserin topline data in Alzheimer’s disease psychosis in Aug–Oct 2026.
Q1 net income was $4 million and cash and investments totaled $851 million at March 31, 2026.
Summary not available.
Acadia Pharmaceuticals (NASDAQ: ACAD) will present at two investor conferences in May 2026: a BofA Securities Health Care Conference fireside chat on May 12, 2026 at 4:20 p.m. PT in Las Vegas and an RBC Capital Markets Global Healthcare Conference fireside chat on May 19, 2026 at 9:00 a.m. ET in New York.
Live webcasts will be available on the company website and archived for roughly one month after each presentation. Acadia highlights its commercial portfolio, including FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and its pipeline in Alzheimer’s disease psychosis and Lewy body dementia psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) will present multiple original data presentations at the 2026 AAN Annual Meeting, April 18–22 in Chicago.
Presentations include Phase 4 real-world LOTUS data on DAYBUE (trofinetide) in adults with Rett syndrome, exploratory pimavanserin (NUPLAZID) analyses in Parkinson’s disease psychosis, and translational and pharmacokinetic research for investigational ACP-711 in essential tremor.
Poster sessions are scheduled April 21–22 with specific poster IDs and times listed for each study.
Acadia Pharmaceuticals (Nasdaq: ACAD) will report first quarter 2026 financial results on May 6, 2026, after U.S. market close. The company will host a conference call and webcast on May 6, 2026 at 4:30 p.m. ET, accessible via acadia.com and archived through August 15, 2026.
Registration is required to receive dial-in details and a unique PIN. Acadia highlights a commercial portfolio with FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome and ongoing mid-to-late stage programs in Alzheimer’s and Lewy body dementia psychosis.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that DAYBUE STIX (trofinetide) powder for oral solution is now broadly available in the United States for treatment of Rett syndrome in patients two years and older. The FDA approved the formulation in December 2025 and bioequivalence testing showed comparable exposure to the original DAYBUE oral solution. DAYBUE STIX is dye- and preservative-free, comes in single-use packets, can be mixed with water-based drinks for taste customization, and is supported by Acadia Connect for financial and prescription assistance. The original oral solution remains available.
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 8:00 a.m. ET. A live webcast will be accessible on the company website under Investors, with an archived recording available for about one month.
Acadia highlighted its commercial portfolio including FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and its mid- to late-stage pipeline in Alzheimer’s disease psychosis and Lewy body dementia psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) appointed Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Audit Committee and brings senior biopharma finance experience, including his role as SVP, Finance at Vertex since March 2020.
This board addition is positioned to strengthen financial and operational oversight as Acadia advances its commercial portfolio and pipeline across neurological and rare diseases.
Acadia Pharmaceuticals (Nasdaq: ACAD) said on March 2, 2026 that the EMA CHMP issued a negative opinion on trofinetide for Rett syndrome; the company intends to request a re-examination.
Acadia noted the pivotal LAVENDER trial met its co-primary and key secondary endpoints, while CHMP raised concerns about effect magnitude at 12 weeks, symptom coverage, and longer-term discontinuations. Trofinetide is approved in the US, Canada and Israel.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported Q4 2025 GAAP total revenues of $284M and FY2025 GAAP total revenues of $1.07B, representing 9% and 12% YoY growth. Non‑GAAP adjusted FY2025 revenues were $1.08B. Q4 NUPLAZID GAAP net sales were $174M and DAYBUE GAAP net sales were $110M.
The company recorded a $20M IRA rebate change in estimate affecting NUPLAZID GAAP sales; FY2026 guidance calls for $1.22–$1.28B total revenues and NUPLAZID sales of $760–$790M.